Clinical Trial Update: Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/tyrosine Kinase Inhibitors with or Without TACE for Advanced HCC with Vascular Invasions

View source ↗

Summary

Clinical trial update on combining immune checkpoint inhibitors with anti-VEGF antibody/tyrosine kinase inhibitors, with or without TACE, for advanced hepatocel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Immune checkpoint inhibitors + anti-VEGF antibody/tyrosine kinase inhibitors (combination therapy) with or without transarterial chemoembolization (TACE)

Snippet

Sponsor: Zhongda Hospital | Conditions: Hepatocellular Carcinoma (HCC) | Status: RECRUITING